Drug and gene electrotransfer in cancer therapy

Publikation: Bidrag til bog/antologi/rapport › Bidrag til bog/antologi › Forskning › fagfællebedømt

Standard

Drug and gene electrotransfer in cancer therapy. / Gehl, Julie.

Somatic Genome Manipulation: Advances, Methods, and Applications. Springer New York, 2015. s. 3-15.

Publikation: Bidrag til bog/antologi/rapport › Bidrag til bog/antologi › Forskning › fagfællebedømt

Harvard

Gehl, J 2015, Drug and gene electrotransfer in cancer therapy. i Somatic Genome Manipulation: Advances, Methods, and Applications. Springer New York, s. 3-15. https://doi.org/10.1007/978-1-4939-2389-2_1

APA

Gehl, J. (2015). Drug and gene electrotransfer in cancer therapy. I Somatic Genome Manipulation: Advances, Methods, and Applications (s. 3-15). Springer New York. https://doi.org/10.1007/978-1-4939-2389-2_1

Vancouver

Gehl J. Drug and gene electrotransfer in cancer therapy. I Somatic Genome Manipulation: Advances, Methods, and Applications. Springer New York. 2015. s. 3-15 https://doi.org/10.1007/978-1-4939-2389-2_1

Author

Gehl, Julie. / Drug and gene electrotransfer in cancer therapy. Somatic Genome Manipulation: Advances, Methods, and Applications. Springer New York, 2015. s. 3-15

Bibtex

@inbook{5829c21523324976b4bef16d362a5628,
title = "Drug and gene electrotransfer in cancer therapy",
abstract = "Drug and gene delivery by electroporation is gaining increasing momentum, in particular delivery of chemotherapeutic agents (electrochemotherapy) is now routinely used in many cancer centers, and gene therapy is in clinical trials. Gene therapy using electrotransfer offers the possibility to create a localized area hosting the transgene, with possibility for (1) local effects on tumors, (2) systemic effect through local activation of the immune system, or (3) local production of the transgenic protein followed by secretion to the systemic circulation, where these drugs may exert desired effects on cancer cells, and/or on supportive structures such as blood vessels. An increasing amount of knowledge is accumulating on important pathways for cancer progression, and this allows discovery of new targets for cancer therapy. Gene therapy offers an easier and less expensive strategy for therapy, since DNA may be produced more easily than formulation of protein drugs, enabling a higher level of access to new potential drugs. Many cancer gene therapy clinical trials are ongoing at this time, and it will be very interesting to follow the clinical results. This chapter reviews the progress in drug and gene electrotransfer, describes the details of the procedure, as well as offers the perspectives for this technology.",
keywords = "Cancer, DNA, Electrochemotherapy, Electroporation, Gene electrotransfer, Personalized medicine, PNA, Signaling pathways",
author = "Julie Gehl",
note = "Publisher Copyright: {\textcopyright} Springer Science+Business Media, LLC 2015.",
year = "2015",
month = jan,
day = "1",
doi = "10.1007/978-1-4939-2389-2_1",
language = "English",
isbn = "9781493923885",
pages = "3--15",
booktitle = "Somatic Genome Manipulation",
publisher = "Springer New York",
address = "United States",

}

RIS

TY - CHAP

T1 - Drug and gene electrotransfer in cancer therapy

AU - Gehl, Julie

N1 - Publisher Copyright: © Springer Science+Business Media, LLC 2015.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Drug and gene delivery by electroporation is gaining increasing momentum, in particular delivery of chemotherapeutic agents (electrochemotherapy) is now routinely used in many cancer centers, and gene therapy is in clinical trials. Gene therapy using electrotransfer offers the possibility to create a localized area hosting the transgene, with possibility for (1) local effects on tumors, (2) systemic effect through local activation of the immune system, or (3) local production of the transgenic protein followed by secretion to the systemic circulation, where these drugs may exert desired effects on cancer cells, and/or on supportive structures such as blood vessels. An increasing amount of knowledge is accumulating on important pathways for cancer progression, and this allows discovery of new targets for cancer therapy. Gene therapy offers an easier and less expensive strategy for therapy, since DNA may be produced more easily than formulation of protein drugs, enabling a higher level of access to new potential drugs. Many cancer gene therapy clinical trials are ongoing at this time, and it will be very interesting to follow the clinical results. This chapter reviews the progress in drug and gene electrotransfer, describes the details of the procedure, as well as offers the perspectives for this technology.

AB - Drug and gene delivery by electroporation is gaining increasing momentum, in particular delivery of chemotherapeutic agents (electrochemotherapy) is now routinely used in many cancer centers, and gene therapy is in clinical trials. Gene therapy using electrotransfer offers the possibility to create a localized area hosting the transgene, with possibility for (1) local effects on tumors, (2) systemic effect through local activation of the immune system, or (3) local production of the transgenic protein followed by secretion to the systemic circulation, where these drugs may exert desired effects on cancer cells, and/or on supportive structures such as blood vessels. An increasing amount of knowledge is accumulating on important pathways for cancer progression, and this allows discovery of new targets for cancer therapy. Gene therapy offers an easier and less expensive strategy for therapy, since DNA may be produced more easily than formulation of protein drugs, enabling a higher level of access to new potential drugs. Many cancer gene therapy clinical trials are ongoing at this time, and it will be very interesting to follow the clinical results. This chapter reviews the progress in drug and gene electrotransfer, describes the details of the procedure, as well as offers the perspectives for this technology.

KW - Cancer

KW - DNA

KW - Electrochemotherapy

KW - Electroporation

KW - Gene electrotransfer

KW - Personalized medicine

KW - PNA

KW - Signaling pathways

UR - http://www.scopus.com/inward/record.url?scp=84944552800&partnerID=8YFLogxK

U2 - 10.1007/978-1-4939-2389-2_1

DO - 10.1007/978-1-4939-2389-2_1

M3 - Book chapter

AN - SCOPUS:84944552800

SN - 9781493923885

SP - 3

EP - 15

BT - Somatic Genome Manipulation

PB - Springer New York

ER -

ID: 318950589